As a general rule, the duration of treatment with Tarivid should be limited to a minimum required for the treatment of diseases, after the susceptibility being confirmed, in order to avoid possible occurrence of resistant bacteria.
Careful Administration: Tarivid should be administered with caution in the following patients: Patients with severe nephropathy. (Persistence of high serum level has been reported.) Patients with or with a history of convulsive diseases eg, epilepsy. (Convulsions may occur.) Patients with a history of hypersensitivity to quinolone antibacterial agents.
Use in pregnancy & lactation: Since the safety of Tarivid in pregnant women has not been established, this product should not be administered to pregnant women or women suspected of being pregnant.
Since ofloxacin is excreted in breast milk, it is recommended to refrain from using this drug in nursing mothers. However, if the administration is absolutely necessary, breastfeeding should be avoided.
Use in children: Since safety in children has not been established, Tarivid should not be administered to children.
Use in the elderly: Tarivid is mainly excreted by the kidneys (see Pharmacology: Pharmacokinetics under Actions). Since the elderly often have renal hypofunction and are in danger of continuous high blood concentration, administer Tarivid with caution.
Since the duration of therapy for leprosy is often long, observe the patient carefully. In the event of any abnormalities, therapy should be discontinued and appropriate measures should be taken.